<DOC>
	<DOC>NCT00630474</DOC>
	<brief_summary>Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.</brief_summary>
	<brief_title>Nasal Decongestion and Obstructive Sleep Apnea</brief_title>
	<detailed_description />
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Sleep Apnea, Obstructive</mesh_term>
	<mesh_term>Xylometazoline</mesh_term>
	<criteria>Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index &gt;10/h) Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months) Nasal surgery within the last 6 months Current treatment with nasal decongestants or topical steroids Sleep disorders other than obstructive sleep apnea Internal medical or psychiatric disorders that interfered with sleep</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>sleep apnea, rhinitis</keyword>
</DOC>